Is Thymosin Alpha-1 Legal in North Carolina?

Print or save as PDF

Key numbers

  • 4 yes and 17 noCommittee vote against adding thymosin alpha-1 to the pharmacy bulks listSource: fda.gov, as cited Nov 7, 2026
  • 1.6 mgDose per vial of Zadaxin, the finished injection sold outside the USSource: fda.gov, as cited Nov 7, 2026
  • 28 amino acidsLength of the thymosin alpha-1 peptide chainSource: fda.gov, as cited Nov 7, 2026
  • FDA approval / None; Drugs@FDA returns no application [1]
  • State-licensed pharmacies / In none of the three interim categories, list updated May 14, 2026 [2]
  • Outsourcing facilities / Category 3, 'nominated without adequate support', list updated March 21, 2025 [3]
  • FDA advisory committee / 4 yes, 17 no against a bulks list listing, December 4, 2024 [5]
  • HHS peptide draft policy, October 2026 / Names six peptides; thymosin alpha-1 is not among them [4]
  • Approved outside the US / Italy, India and Hong Kong; Zadaxin 1.6 mg injection [1]

Is thymosin alpha-1 FDA-approved?

No. FDA's Drugs@FDA search returns no application for it [1]. It holds four US orphan drug designations, but orphan designation is a separate process from approval and is not an approval [1].

The peptide is 28 amino acids long and was originally isolated from thymosin fraction 5; thymalfasin is the synthetic version with the same sequence, and the finished injection sold elsewhere is Zadaxin, 1.6 mg per vial, which is not interchangeable with bulk thymosin alpha-1 powder [1].

Can a pharmacy compound it?

For state-licensed pharmacies and physicians, FDA's list sorts nominated bulk substances into three categories. On the version updated May 14, 2026, thymosin alpha-1 is in none of the three, and FDA's category 1 policy, generally no action against compounders when conditions are met, does not apply to it [2][3].

For outsourcing facilities, FDA's list updated March 21, 2025 places it in category 3, 'nominated without adequate support' [3].

It was previously in category 2, the significant-safety-risk group. FDA's page on those substances, content dated April 22, 2026, now lists it in the 'nominated but withdrawn' table, having come off that list because the nominators withdrew [6]. FDA's posted concerns stayed up: significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [6].

FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate on December 4, 2024, when asked whether to add thymosin alpha-1 to the pharmacy bulks list; members who voted no cited no compelling evidence of clinical effectiveness and safety [5]. HHS's October 2026 draft enforcement-discretion policy for peptides names six, BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500, and thymosin alpha-1 is not one of them [4].

Questions worth asking

Choose the questions you want to keep

Is it approved in other countries?

FDA's December 2024 review lists authorizations in Italy, as an adjuvant to influenza vaccination in immunocompromised people; in India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and in Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].

Wider counts come from sources tied to the product's developer. A SciClone 2014 annual report claims approvals in parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, which FDA said it could not independently verify, and two older reviews by authors tied to the Zadaxin developer say 'over 35 countries' in 2009 and 'more than 30 countries' in 2007 [1][7][8]. The Italian label says the product is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. What does FDA's Drugs@FDA search return for thymosin alpha-1?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is thymosin alpha-1 legal in North Carolina?
FDA's lists give no identified authorization for a state-licensed pharmacy to compound it: it is not FDA-approved, it sits in none of the three categories for state-licensed pharmacies, and FDA's advisory committee voted 4 to 17 against adding it to the bulks list [1][2][5].
Is thymosin alpha-1 FDA-approved in the United States?
No. FDA's Drugs@FDA search returns no application for it, and its four US orphan drug designations are not approvals [1].
Can an outsourcing facility compound thymosin alpha-1?
On FDA's list for outsourcing facilities, updated March 21, 2025, it sits in category 3, nominated without adequate support [3]. FDA also proposed that it not be added to the pharmacy bulks list, and the advisory committee voted 4 yes and 17 no on December 4, 2024 [5].
Where is Zadaxin approved?
FDA's December 2024 review lists Italy, India and Hong Kong; the European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].
Show all 8 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in North Carolina?